Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations
A method is provided for improving lung function in COPD by administering a muscarinic antagonist with a high efficiency nebulizer.
1. A pharmaceutical composition, comprising an aqueous solution of glycopyrrolate having a volume of about 0.7 mL to about 1.0 mL, a glycopyrrolate concentration of about 25 μg/mL to about 400 μg/mL, and a pH of about 3 to about 5, wherein the solution is free of other bronchodilating agents and is substantially free of preservatives.
2. The pharmaceutical composition of claim 1 , further comprising an organic acid.
3. The pharmaceutical composition of claim 2 , wherein the organic acid is citric acid or a pharmaceutically acceptable salt thereof.
4. The pharmaceutical composition of claim 1 , wherein the solution is substantially free of benzyl alcohol.
5. The pharmaceutical composition of claim 1 , wherein the glycopyrrolate concentration is about 25 μg/mL.
6. The pharmaceutical composition of claim 1 , wherein the volume is about 1 mL.
7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is contained in a single dose ampule.
8. The pharmaceutical composition of claim 1 , comprising an aqueous solution of glycopyrrolate having a volume of about 1.0 mL, a glycopyrrolate concentration of about 25 μg/mL, and a pH of about 3 to about 5, wherein the solution is free of other bronchodilating agents and is substantially free of preservatives.
9. The pharmaceutical composition of claim 8 , wherein said aqueous solution further comprises citric acid or a pharmaceutically acceptable salt thereof.
10. A method of treating chronic obstructive pulmonary disease (COPD) in a subject comprising administering to the subject a pharmaceutical composition via a high efficiency nebulizer, wherein the pharmaceutical composition comprises an aqueous solution of glycopyrrolate having a volume of about 0.7 mL to about 1.0 mL, a glycopyrrolate concentration of about 25 μg/mL to about 400 μg/mL, and a pH of about 3 to about 5, wherein the solution is free of other bronchodilating agents and is substantially free of preservatives.
11. The method of claim 10 , wherein the pharmaceutical composition further comprises an organic acid.
12. The method of claim 11 , wherein the organic acid is citric acid or a pharmaceutically acceptable salt thereof.
13. The method of claim 10 , wherein the solution is substantially free of benzyl alcohol.
14. The method of claim 10 , wherein the glycopyrrolate concentration is about 25 μg/mL.
15. The method of claim 10 , wherein the volume is about 1 mL.
16. The method of claim 10 , wherein the pharmaceutical composition is contained in a single dose ampule.
17. The method of claim 10 , wherein the pharmaceutical composition comprises an aqueous solution of glycopyrrolate having a volume of about 1.0 mL, a glycopyrrolate concentration of about 25 μg/mL, and a pH of about 3 to about 5, wherein the solution is free of other bronchodilating agents and is substantially free of preservatives.
18. The method of claim 17 , wherein said aqueous solution further comprises citric acid or a pharmaceutically acceptable salt thereof.